Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil
This NMA provides valuable evidence to support rational therapeutic choices for RR-CLL in Brazil, highlighting VenR and Bruton tyrosine kinase inhibitors as leading treatment options across diverse clinical scenarios.
Authors
- M A Correia
- Maria Isabel Duran
- Natália Santoni
- Bruno M. Barros
- Carlos S. Magliano
- Andreas Duva
- Pedro Vitor P. Lima
- Márcia Gisele S. Costa
Institutions
- Brazilian Development Bank (BR)
- Instituto Nacional de Cardiologia (BR)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1007/s40487-026-00418-x
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00